

PCT


INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference P7057W0 CTH		of Transmittal of International Search Report /220) as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/CP 00/02429	22/06/2000	25/06/1000
PCT/GB 00/02428	23/06/2000	25/06/1999
Applicant		
IMERIAL COLLEGE OF SCIENC	E, TECHNOLOGY AND MEDICINE	
This International Search Report has bee according to Article 18. A copy is being tr	n prepared by this International Searching At ansmitted to the International Bureau.	uthority and is transmitted to the applicant
This International Search Report consists	of a total of5sheets.	
	a copy of each prior art document cited in th	is report.
Basis of the report		
 a. With regard to the language, the language in which it was filed, un 	international search was carried out on the bless otherwise indicated under this item.	asis of the international application in the
the international search w Authority (Rule 23.1(b)).	vas carried out on the basis of a translation of	the international application furnished to this
b. With regard to any nucleotide ar was carried out on the basis of the		international application, the international search
	onal application in written form.	
filed together with the inte	ernational application in computer readable fo	rm.
furnished subsequently to	this Authority in written form.	
X furnished subsequently to	this Authority in computer readble form.	
	bsequently furnished written sequence listing as filed has been furnished.	does not go beyond the disclosure in the
the statement that the infefurnished	ormation recorded in computer readable form	is identical to the written sequence listing has been
2. X Certain claims were fou	ind unsearchable (See Box I).	
3. Unity of Invention is lac	king (see Box II).	
4. With regard to the title ,		
the text is approved as su	ubmitted by the applicant.	
the text has been establis	shed by this Authority to read as follows:	
5. With regard to the abstract,		
the text is approved as su	ubmitted by the applicant.	
	shed, according to Rule 38.2(b), by this Autho e date of mailing of this international search ro	rity as it appears in Box III. The applicant may, eport, submit comments to this Authority.
6. The figure of the drawings to be pub	lished with the abstract is Figure No.	
as suggested by the appl	icant.	X None of the figures.
because the applicant fail	led to suggest a figure.	
because this figure better	characterizes the invention.	



			, - <u>-</u>
A. CLASSI IPC 7	FICATION OF SUBJECT MATTER C12N15/31 C07K14/33 A61K39/	08	
According to	o International Patent Classification (IPC) or to both national classific	eation and IPC	
	SEARCHED		
Minimum do IPC 7	ocumentation searched (classification system followed by classification C12N C07K A61K	ion symbols)	
Documenta:	tion searched other than minimum documentation to the extent that s	such documents are included in the fields s	earched
Electronic d	ata base consulted during the international search (name of data ba	ase and, where practical, search terms used	i)
EPO-In	ternal, WPI Data, PAJ, BIOSIS, EMBAS	SE, MEDLINE, EMBL	
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the rel	levant passages	Relevant to claim No.
X	FIGUEIREDO D ET AL.: "Characteri recombinant tetanus toxin derivat suitable for vaccine development' INFECTION AND IMMUNITY, vol. 63, no. 8, August 1995 (1995 pages 3218-3221, XP002151794 abstract figures 1,3; table 1 page 3221, left-hand column, line	tives " 5-08),	1-14
X Furth	ner documents are listed in the continuation of box C.	χ Patent family members are listed	in annex.
"A" docume consid "E" earlier of filing de which is citation "O" docume other n	nt which may throw doubts on priority claim(s) or is cited to establish the publication date of another n or other special reason (as specified) on treferring to an oral disclosure, use, exhibition or	"T" later document published after the inte or priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the do "Y" document of particular relevance; the cannot be considered to involve an indocument is combined with one or moments, such combined with one or moments, such combination being obvious in the art.	the application but early underlying the claimed invention be considered to cument is taken alone claimed invention ventive step when the pre other such docuust o a person skilled
Date of the a	actual completion of the international search	Date of mailing of the international sea	arch report
7	November 2000	22/11/2000	
Name and m	nailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer van de Kamp, M	



0.40	-N) POOLINGING CONCIDENTS TO BE SELEVAND	P 8 00/02428
C.(Continua Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Category	Gradult of document, with indication, where appropriate, of the relevant passages	neevant to daim no.
X	HALPERN J L ET AL.: "Characterization of the receptor-binding domain of tetanus toxin" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 15, 25 May 1993 (1993-05-25), pages 11188-11192, XP002151795	1-8, 11-16
Υ	cited in the application abstract figures 1,3	9,10
Υ	EP 0 209 281 A (WELLCOME FOUND) 21 January 1987 (1987-01-21) cited in the application examples 4,8,9 claims 14-16 figure 2	9,10
Α	SHAPIRO R E ET AL.: "Identification of a ganglioside recognition domain of tetanus toxin using a novel ganglioside photoaffinity ligand" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 48, 28 November 1997 (1997-11-28), pages 30380-30386, XP002151796 cited in the application abstract	1,15,16
A	ANDERSON R ET AL: "Immunization of mice with DNA encoding fragment C of tetanus toxin" VACCINE, vol. 15, no. 8, 1 June 1997 (1997-06-01), pages 827-829, XP004075662 abstract page 827, left-hand column, line 10-28 page 828, right-hand column, line 29-35	1,9,10
A	WO 94 00487 A (US ARMY) 6 January 1994 (1994-01-06) page 4, line 18 -page 5, line 6 example 5	10,11, 13-15
A	UMLAND T C ET AL.: "Structure of the receptor binding fragment HC of tetanus toxin" NATURE STRUCTURAL BIOLOGY, vol. 4, no. 10, October 1997 (1997-10), pages 788-792, XP000952554 cited in the application abstract page 789, right-hand column, line 1 -page 790, left-hand column, line 22	1,15,16
	-/	



	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	·
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HALPERN J L ET AL.: "Neurospecific binding, internalization, and retrograde axonal transport" CURR. TOP. MICROBIOL. IMMUNOL., vol. 195, 1995, pages 221-241, XP000960426 the whole document	1-16
T	SINHA K ET AL.: "Analysis of mutants of tetanus toxin HC fragment: ganglioside binding, cell binding and retrograde axonal transport properties" MOLECULAR MICROBIOLOGY, vol. 37, no. 5, September 2000 (2000-09), pages 1041-1051, XP000952564 the whole document	1-16

nform on patent family members

Published Police B 00/02428

Patent document cited in search report		Publication date	Patent family member(s)		Publication date	
EP 0209281	А	21-01-1987	AU DK ES FI JP ZA	5941486 A 307986 A 2000255 A 862761 A 62051994 A 8604805 A	08-01-1987 29-12-1986 01-02-1988 29-12-1986 06-03-1987 24-02-1988	
WO 9400487	Α	06-01-1994	AU US	4545393 A 5601826 A	24-01-1994 11-02-1997	

(19) World Intellectual Property Organizati n International Bureau



(43) International Publication Date 4 January 2001 (04.01.2001)

PCT

(10) International Publication Number WO 01/00839 A1

- (51) International Patent Classification⁷: C07K 14/33, A61K 39/08
- C12N 15/31,
- (21) International Application Number: PCT/GB00/02428
- (22) International Filing Date: 23 June 2000 (23.06.2000)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 9914861.1

25 June 1999 (25.06.1999) GB

- (71) Applicant (for all designated States except US): IMPE-RIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE [GB/GB]; Sherfield Building, Exhibition Road, London SW7 2AZ (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only). FAIRWEATHER, Neil, Fraser [GB/GB]; 1 The Drive, Bexley, Kent DA3 3DH (GB). SINHA, Katharine [GB/GB]; Imperial College, Dept. of Biochemistry, South Kensington, London SW7 2AY (GB).

- (74) Agents: HARDING, Charles, Thomas et al.; D Young & Co., 21 New Fetter Lane, London EC4A 1DA (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TETANUS TOXIN POLYPEPTIDES

(57) Abstract: A polypeptide is provided which polypeptide comprises tetanus toxin (TeNT) fragment C, or an immunogenic fragment thereof, which tetanus toxin fragment C, or immunogenic fragment thereof comprises a mutation in a loop region, which mutation results in: a reduction in the binding of the tetanus toxin fragment C, or immunogenic fragment thereof, to gangliosides; and/or a reduction in the binding of the tetanus toxin fragment C, or immunogenic fragment thereof, to primary motoneurones; and/or a reduction in the ability of the tetanus toxin fragment C, or immunogenic fragment thereof, to undergo retrograde transport.

01/00839



Int. onal Application No PCT/GB 00/02428

		PC1/GB 00,	/ 02420
A. CLASSIF IPC 7	ication of subject matter C12N15/31 C07K14/33 A61K39/0	8	
According to	International Patent Classification (IPC) or to both national classification	ation and IPC	
B. FIELDS			
Minimum doo IPC 7	currentation searched (classification system followed by classification C12N C07K A61K	on symbols)	
	on searched other than minimum documentation to the extent that s		
	ata base consulted during the international search (name of data base ternal, WPI Data, PAJ, BIOSIS, EMBAS		,
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the rel	evant passages	Relevant to claim No.
X	FIGUEIREDO D ET AL.: "Characteri recombinant tetanus toxin derivat suitable for vaccine development' INFECTION AND IMMUNITY, vol. 63, no. 8, August 1995 (1995 pages 3218-3221, XP002151794 abstract figures 1,3; table 1 page 3221, left-hand column, line	tives 5-08),	1-14
X Furt	ther documents are listed in the continuation of box C.	Patent family members are listed	i in annex.
"A" docum consi "E" earlier filing "L" docum which citatic "O" docum other "P" docum later	ategories of cited documents: lent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date lent which may throw doubts on priority claim(s) or is cited to establish the publication date of another on or other special reason (as specified) nent referring to an oral disclosure, use, exhibition or means tent published prior to the international filing date but than the priority date claimed	"T" later document published after the intro or priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the de "Y" document of particular relevance; the cannot be considered to involve an indocument is combined with one or ments, such combination being obvious in the art. "&" document member of the same patern."	n the application but neory underlying the claimed invention at be considered to coment is taken alone claimed invention nventive step when the love other such docupous to a person skilled t family
7	7 November 2000	22/11/2000	
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Van de Kamp, M	

3



Ins. onal Application No PCT/GB 00/02428


Mich DOCUMENTO CONCIDENCE TO BE CONTINUED.	PC1/GB 00/02428
	Relevant to claim No.
HALPERN J L ET AL.: "Characterization of the receptor-binding domain of tetanus toxin" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 15, 25 May 1993 (1993-05-25), pages 11188-11192, XP002151795	1-8, 11-16
cited in the application abstract figures 1,3	9,10
EP 0 209 281 A (WELLCOME FOUND) 21 January 1987 (1987-01-21) cited in the application examples 4,8,9 claims 14-16 figure 2	9,10
SHAPIRO R E ET AL.: "Identification of a ganglioside recognition domain of tetanus toxin using a novel ganglioside photoaffinity ligand" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 48, 28 November 1997 (1997-11-28), pages 30380-30386, XP002151796 cited in the application abstract	1,15,16
ANDERSON R ET AL: "Immunization of mice with DNA encoding fragment C of tetanus toxin" VACCINE, vol. 15, no. 8, 1 June 1997 (1997-06-01), pages 827-829, XP004075662 abstract page 827, left-hand column, line 10-28 page 828, right-hand column, line 29-35	1,9,10
WO 94 00487 A (US ARMY) 6 January 1994 (1994-01-06) page 4, line 18 -page 5, line 6 example 5	10,11, 13-15
UMLAND T C ET AL.: "Structure of the receptor binding fragment HC of tetanus toxin" NATURE STRUCTURAL BIOLOGY, vol. 4, no. 10, October 1997 (1997-10), pages 788-792, XP000952554 cited in the application abstract page 789, right-hand column, line 1 -page 790, left-hand column, line 22	1,15,16
	HALPERN J L ET AL.: "Characterization of the receptor-binding domain of tetanus toxin" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 15, 25 May 1993 (1993-05-25), pages 11188-11192, XPO02151795 cited in the application abstract figures 1,3 EP 0 209 281 A (WELLCOME FOUND) 21 January 1987 (1987-01-21) cited in the application examples 4,8,9 claims 14-16 figure 2 SHAPIRO R E ET AL.: "Identification of a ganglioside recognition domain of tetanus toxin using a novel ganglioside photoaffinity ligand" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 48, 28 November 1997 (1997-11-28), pages 30380-30386, XP002151796 cited in the application abstract ANDERSON R ET AL: "Immunization of mice with DNA encoding fragment C of tetanus toxin" VACCINE, vol. 15, no. 8, 1 June 1997 (1997-06-01), pages 827-829, XP004075662 abstract page 827, left-hand column, line 10-28 page 828, right-hand column, line 29-35 WO 94 00487 A (US ARMY) 6 January 1994 (1994-01-06) page 4, line 18 -page 5, line 6 example 5 UMLAND T C ET AL.: "Structure of the receptor binding fragment HC of tetanus toxin" NATURE STRUCTURAL BIOLOGY, vol. 4, no. 10, October 1997 (1997-10), pages 788-792, XP000952554 cited in the application abstract page 789, right-hand column, line 1 -page 790, left-hand column, line 22



In ional Application No PCT/GB 00/02428

		PC1/GB 00,	
C.(Continue	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages		Relev unt to claim No.
A	HALPERN J L ET AL.: "Neurospecific binding, internalization, and retrograde axonal transport" CURR. TOP. MICROBIOL. IMMUNOL., vol. 195, 1995, pages 221-241, XP000960426 the whole document		1-16
T	SINHA K ET AL.: "Analysis of mutants of tetanus toxin HC fragment: ganglioside binding, cell binding and retrograde axonal transport properties" MOLECULAR MICROBIOLOGY, vol. 37, no. 5, September 2000 (2000-09), pages 1041-1051, XP000952564 the whole document		1-16







information on patent family members

Ir Ional Application No PCT/GB 00/02428

Patent document cited in search report		Publication date		Patent family member(s)	Publication dat	
EP 0209281	A	21-01-1987	AU DK ES FI JP ZA	5941486 A 307986 A 2000255 A 862761 A 62051994 A 8604805 A	08-01-1987 29-12-1986 01-02-1988 29-12-1986 06-03-1987 24-02-1988	
WO 9400487	A	06-01-1994	AU US	4545393 A 5601826 A	24-01-1994 11-02-1997	

+01703 224262

P.34 R-390 Job-961

25-06-99 16:25 P.34


Figure 1

FRX NO.: + 01703 224262



FRX No.: + 01703 224262

2/2




+01703 224262

ERX NO.: + 01703 224262

P.34 R-390 Job-961


25-06-99 16:25 P.34

Figure 1



2/2

FRX NO.: + 01703 224262



TENT COOPERATION TRE

REC'D 2 0 SEP 2001 WIPO

PCT

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or age	ent's file reference	T				
P7057WO CT		FOR FURTHER ACT		ee Notification of Transmittal of International reliminary Examination Report (Form PCT/IPEA/416)		
International appli	cation No.	International filing date (da	ay/month/yea	Priority date (day/month/year)		
PCT/GB00/02	428	23/06/2000		25/06/1999		
International Pate C12N15/31	nt Classification (IPC) or na	tional classification and IPC				
Applicant In F		TECHNOLOGY AND M	MEDICINE			
	ational preliminary exami smitted to the applicant a		repared by	this International Preliminary Examining Authority		
2. This REPO	RT consists of a total of	7 sheets, including this c	cover sheet	· ·		
☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).						
These annexes consist of a total of sheets.						
3. This report	contains indications rela	ting to the following items	s:			
ı 🛛	Basis of the report					
11 🗆	Priority					
III ⊠	Non-establishment of o	pinion with regard to nove	elty, inventi	ve step and industrial applicability		
IV 🗆	Lack of unity of invention	n				
∨ ⊠		nder Article 35(2) with reg		elty, inventive step or industrial applicability;		
VI 🗆	Certain documents cite	ed				
VII 🗆	Certain defects in the in	ternational application				
VIII ⊠	Certain observations or	the international applica	tion			
Date of submission of the demand			Date of comp	oletion of this report		
05/01/2001			18.09.2001			
preliminary examir	•	, , , , , , , , , , , , , , , , , , ,	Authorized of	fficer		
(6) D-80	pean Patent Office 298 Munich +49 89 2399 - 0 Tx: 523656	epmu d	Huber, A	(Lange State of the Control of the C		
Fax:	+49 89 2399 - 4465	1	Telephone N	0. +49 89 2399 8173		

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/02428

	I.	Basis	of the	r	р	rt
--	----	-------	--------	---	---	----

1.	the and	receiving Office in	ments of the international application (Replacement sheets which have been furnished to response to an invitation under Article 14 are referred to in this report as "originally filed" o this report since they do not contain amendments (Rules 70.16 and 70.17)):
	1-3	3	as originally filed
	Cla	ims, No.:	
	1-1	6	as originally filed
	Dra	wings, sheets:	
	1/2-	-2/2	as originally filed
	Sec	quence listing part	of the description, pages:
	1-9,	, filed with the letter	of 11.08.2000
2.			guage, all the elements marked above were available or furnished to this Authority in the international application was filed, unless otherwise indicated under this item.
	The	se elements were a	available or furnished to this Authority in the following language: , which is:
		the language of a	translation furnished for the purposes of the international search (under Rule 23.1(b)).
		the language of pu	ublication of the international application (under Rule 48.3(b)).
		the language of a 55.2 and/or 55.3).	translation furnished for the purposes of international preliminary examination (under Rule
3.			eleotide and/or amino acid sequence disclosed in the international application, the y examination was carried out on the basis of the sequence listing:
		contained in the in	ternational application in written form.
		filed together with	the international application in computer readable form.
	\boxtimes	furnished subsequ	ently to this Authority in written form.
	\boxtimes	furnished subsequ	ently to this Authority in computer readable form.
	×		t the subsequently furnished written sequence listing does not go beyond the disclosure in oplication as filed has been furnished.
	×	The statement that	t the information recorded in computer readable form is identical to the written sequence

4. The amendments have resulted in the cancellation of:

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/02428

		the description,	pages:			
		the claims,	Nos.:			
		the drawings,	sheets:			
5.		This report has been established as if (some of) the amendments had not been made, since they have considered to go beyond the disclosure as filed (Rule 70.2(c)):				
		(Any replacement st report.)	neet containing such amendments must be referred to under item 1 and annexed to this			
6.	Add	additional observations, if necessary:				
III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
1.	 The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- obvious), or to be industrially applicable have not been examined in respect of: 					
		the entire internation	al application.			
	×	claims Nos. 11, 13, 1	4 (IA).			
because:						
	_					
	the said international application, or the said claims Nos. 11, 13, 14 (IA) relate to the following subject matt which does not require an international preliminary examination (specify): see separate sheet					
	☐ the description, claims or drawings (indicate particular elements below) or said claims Nos, are so uncle					
		that no meaningful of	s or drawings (indicate particular elements below) or said claims Nos. are so unclear pinion could be formed (specify):			
		the claims, or said cla could be formed.	aims Nos. are so inadequately supported by the description that no meaningful opinion			
		no international searc	ch report has been established for the said claims Nos			
 A meaningful international preliminary examination cannot be carried out due to the failure of the and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Instructions: 		I preliminary examination cannot be carried out due to the failure of the nucleotide ce listing to comply with the standard provided for in Annex C of the Administrative				
		the written form has r	not been furnished or does not comply with the standard.			
			e form has not been furnished or does not comply with the standard.			
٧.	Rea	soned statement und	der Article 35(2) with regard to novelty, inventive step or industrial applicability;			

citations and explanations supporting such statement

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/02428

1. Statement

Novelty (N)

Yes: Claims 4

No: Claims

Claims 1-3, 5-9, 15, 16

Inventive step (IS)

Yes:

Claims 4

No:

Claims 10-14

Industrial applicability (IA)

Yes:

Claims 1-10, 12, 15, 16

No: Claims

2. Citations and explanations see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made: see separate sheet

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 11, 13 and 14 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

For the assessment of the above claims on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- 1. Reference is made to the following documents:
 - D1: FIGUEIREDO D ET AL.: 'Characterization of recombinant tetanus toxin derivatives suitable for vaccine development' INFECTION AND IMMUNITY. vol. 63, no. 8, August 1995 (1995-08), pages 3218-3221, XP002151794
 - D2: HALPERN J L ET AL.: 'Characterization of the receptor-binding domain of tetanus toxin' JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 15, 25 May 1993 (1993-05-25), pages 11188-11192, XP002151795 cited in the application

 D1 discloses recombinant tetanus toxin derivatives suitable for vaccine development. Immunogenic derivatives of fragment C that have lost the ability to bind neurons and which lack C-terminal amino acids are described (e.g. TetC 1-180; TetC 1-271).

The polypeptide of Claim 1 is defined as comprising fragment C or an immunogenic fragment thereof, wherein said fragment C (or immunogenic fragment thereof) **comprises** a mutation in a loop region, thus the mutation must not be limited to a loop region.

The immunogenic mutants of D1 are also mutated within a loop region and exhibit reduced neuron binding.

The subject-matter of Claims 1-3 and 5-9 is therefore anticipated by the teaching of D1 (Art. 33(2) PCT).

Claims 10-14 are directed to a vaccine comprising a polypeptide of Claims 1-14, a polynucleotide according to Claim 5 or a vector according to Claim 6, methods of treating, preventing or reducing the susceptibility to C. tetani infection by administration of the polypeptide, polynucleotide or vector, the use thereof for preparing antibodies, a method for producing antibodies and a method of treating C. tetani infection by administration of said antibodies. The use of the fragment C derivatives of D1 for vaccine development, in particular of those derivatives that do not bind neurons is clearly suggested in D1. The subject-matter of Claim 10-14 therefore lacks the required inventive step (Art. 33(3) PCT).

D2 describes the involvement of the carboxy-terminal half of heavy chain (C fragment) of tetanus toxin in ganglioside and neuron binding.

Deletion of 10 or more C-terminal amino acids resulted in a complete loss of ganglioside binding. Deletion mutant Hc1-435 comprises deletion of at least one amino acid residue within a loop region (aa 1282). D2 is therefore novelty-destroying for the subject-matter of Claims 1-3, 5, 15 and 16.

Claim 4 is directed to specific deletion mutants of TeNT fragment C, which have neither been disclosed nor rendered obvious in the cited documents. Novelty and inventive step of the subject-matter of Claim 4 are therefore acknowledged.

EXAMINATION REPORT - SEPARATE SHEET

Re It m VIII

Certain observations on the international application

Claim 16 is directed to a polypeptide produced by the method of Claim 15. Claim 15 is, however, not directed to a method of producing a polypeptide but concerns a method for reducing the binding affinity of a TeNT fragment C polypeptide comprising modifying one or more amino acids of said polypeptide. Claim 16 is therefore not correctly dependent on Claim 15. It should also be noted that a polypeptide with reduced binding affinity to gangliosides in which one or more amino acids in a surface exposed loop region of TeNT fragment C are modified is already covered by Claim 1. Claim 16 therefore appears to be redundant.

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

FAIRWEATHER, Neil, Fraser et al

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202

Date of mailing (day/month/year) ETATS-UNIS D'AMERIQUE

19 February 2001 (19.02.01) in its capacity as elected Office

International application No.
PCT/GB00/02428
P7057WO CTH

International filing date (day/month/year)
23 June 2000 (23.06.00)
Priority date (day/month/year)
25 June 1999 (25.06.99)

_	notified of its election made: ne International Preliminary Examining Authority on: 05 January 2001 (05.01.01) election filed with the International Bureau on:	-
2. The election X was was not made before the expiration of 19 Rule 32.2(b).	months from the priority date or, where Rule 32 appli	ies, within the time limit under
Rule 32.2(b).		

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Pascal Piriou

Telephone No.: (41-22) 338.83.38

Facsimile No.: (41-22) 740.14.35